Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants

NCT04765384 is registered in ClinicalTrials.gov with Janssen Vaccines & Prevention B.V. as lead sponsor.

NCT NCT04765384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04765384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants
Lead sponsor
Janssen Vaccines & Prevention B.V.
Phase
Phase 2
Overall status
Completed
Start date
August 27, 2021
Completion date
November 24, 2023
Enrollment
51 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 prevention